E2007

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuralgia

Conditions

Neuralgia

Trial Timeline

Jan 1, 2008 → Jul 1, 2011

NCT ID

NCT00592904

About E2007

E2007 is a phase 2/3 stage product being developed by Eisai for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00592904. Target conditions include Neuralgia.

What happened to similar drugs?

8 of 18 similar drugs in Neuralgia were approved

Approved (8) Terminated (3) Active (8)

✅QUTENZAAstellas PharmaApproved

✅GalcanezumabEli LillyApproved

✅Etoricoxib + PlaceboMerckApproved

✅pregabalinPfizerApproved

✅Lyrica (pregabalin) + PlaceboPfizerApproved

✅pregabalin + PlaceboPfizerApproved

✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03201900	Phase 3	Completed	Jun 28, 2017	Jul 27, 2020	Partial Onset Seizures
NCT02116907	Phase 1	Completed	May 1, 2014	Sep 1, 2014	Healthy Subjects
NCT00849212	Phase 2	Completed	Apr 1, 2009	Nov 1, 2009	Refractory Partial Seizures
NCT00592904	Phase 2/3	Completed	Jan 1, 2008	Jul 1, 2011	Neuralgia
NCT00451633	Phase 2	Withdrawn	Mar 1, 2007	—	Parkinson's Disease
NCT00427011	Phase 2	Terminated	Feb 1, 2007	Apr 1, 2008	Parkinson's Disease
NCT00360412	Phase 3	Terminated	Oct 1, 2006	Apr 1, 2008	Parkinson's Disease
NCT00286897	Phase 3	Completed	Feb 1, 2006	Aug 1, 2007	Parkinson's Disease
NCT00165789	Phase 2	Completed	Sep 1, 2005	Sep 1, 2006	Parkinson's Disease
NCT00154063	Phase 2	Completed	Jan 1, 2005	Jun 1, 2006	Migraine Prophylaxis

Competing Products

20 competing products in Neuralgia

See all competitors

Product	Company	Stage	Hype Score
Placebo + DS-5565	Daiichi Sankyo	Pre-clinical	26
QUTENZA	Astellas Pharma	Approved	43
ASP8477 + Placebo	Astellas Pharma	Phase 2	35
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Galcanezumab	Eli Lilly	Approved	43
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine	AbbVie	Phase 2	35
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
Cetuximab + Placebo	Merck	Phase 2	35
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
EMA401 + Placebo	Novartis	Phase 2	27
pregabalin	Pfizer	Approved	43
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43
2-weeks placebo then gabapentin + 1-week placebo then gabapentin	Pfizer	Pre-clinical	26